CRISM Therapeutics Corp - Surrey-headquartered pharmaceutical firm - Granted a European patent for its lead product ChemoSeed by the European Patent Office. This covers the manufacturing process for the preparation of chemotherapeutic drug implants and their use in therapy, particularly in treating brain tumours such as high grade glioma. ChemoSeed facilitates the local delivery of irinotecan directly to the brain tumour resection site, which allows the delivery of larger doses and reduces systemic concentrations. This alleviates traditional side effects for the patient.

Chief Executive Officer Andrew Webb says: ‘This provides CRISM [intellectual property] protection in one of our key markets, whilst enhancing ChemoSeed’s appeal to potential commercial partners. The board believes that ChemoSeed could improve therapeutic outcomes for brain tumour patients and we look forward to demonstrating this as we prepare for a clinical trial in 2025.’

Current stock price: 12.00 pence

12-month change: up 4.4%

Copyright 2024 Alliance News Ltd. All Rights Reserved.